RxSight (RXST) Competitors

PROCEPT BioRobotics (NASDAQ:PRCT) and RxSight (NASDAQ:RXST) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability.

Does the media favor PRCT or RXST?

In the previous week, PROCEPT BioRobotics had 4 more articles in the media than RxSight. MarketBeat recorded 15 mentions for PROCEPT BioRobotics and 11 mentions for RxSight. PROCEPT BioRobotics' average media sentiment score of 0.74 beat RxSight's score of -0.08 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	8 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is PRCT or RXST more profitable?

RxSight has a net margin of -23.92% compared to PROCEPT BioRobotics' net margin of -50.07%. RxSight's return on equity of -14.00% beat PROCEPT BioRobotics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-50.07%	-38.57%	-26.06%
RxSight	-23.92%	-14.00%	-12.51%

Do insiders & institutionals believe in PRCT or RXST?

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 17.4% of PROCEPT BioRobotics shares are owned by insiders. Comparatively, 9.4% of RxSight shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Do analysts rate PRCT or RXST?

PROCEPT BioRobotics currently has a consensus target price of $94.29, indicating a potential upside of 51.89%. RxSight has a consensus target price of $49.33, indicating a potential upside of 85.93%. Given RxSight's higher probable upside, analysts clearly believe RxSight is more favorable than PROCEPT BioRobotics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
RxSight	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Which has stronger earnings & valuation, PRCT or RXST?

RxSight has lower revenue, but higher earnings than PROCEPT BioRobotics. RxSight is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$224.50M	15.16	-$105.90M	-$1.76	-35.27
RxSight	$139.93M	7.68	-$48.61M	-$0.72	-36.85

Does the MarketBeat Community believe in PRCT or RXST?

RxSight received 10 more outperform votes than PROCEPT BioRobotics when rated by MarketBeat users. However, 68.97% of users gave PROCEPT BioRobotics an outperform vote while only 66.67% of users gave RxSight an outperform vote.

Company	Underperform	Outperform
PROCEPT BioRobotics	Outperform Votes 40 68.97%	Underperform Votes 18 31.03%
RxSight	Outperform Votes 50 66.67%	Underperform Votes 25 33.33%

Which has more risk & volatility, PRCT or RXST?

PROCEPT BioRobotics has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, RxSight has a beta of 1.22, meaning that its stock price is 22% more volatile than the S&P 500.

Summary

PROCEPT BioRobotics and RxSight tied by winning 9 of the 18 factors compared between the two stocks.